Therapy News and Research

RSS

EMD Serono submits NDA for Cladribine Tablets in the U.S.

EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, Germany, announced today the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS).

1 Oct 2009

National Institutes of Health awards $16.8 million grant to Hutchinson Center/UW group

The National Heart, Lung and Blood Institute of the National Institutes of Health has awarded a $16.8 million, seven-year grant to launch a bicoastal research partnership between Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium and Children's Hospital of Philadelphia.

30 Sep 2009

MacuSight's clinical development update on its proprietary ocular sirolimus product

MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today provided a clinical development update for Perceiva, the company's proprietary ocular sirolimus product.

30 Sep 2009

Amicus Therapeutics to initiate Phase 1 study of AT2220

Amicus Therapeutics today announced it plans to initiate a Phase 1 study of AT2220 (1-deoxynojirimycin HCl), its investigational drug in development for the treatment of Pompe Disease.

30 Sep 2009

Lumenis to discuss different treatment options for laryngeal cancer at 2009 AAO-HNS

Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.

From Lumenis Inc. 30 Sep 2009

Æterna Zentaris announces results of its cetrorelix pamoate clinical development program TQT trial

Æterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that the 043 Thorough QT (TQT) trial, which is part of the cetrorelix pamoate clinical development program in benign prostatic hyperplasia (BPH), met its primary endpoint.

30 Sep 2009

St. Jude Medical launches new cardiac rhythm management devices

St. Jude Medical, Inc. today announced it has launched several new cardiac rhythm management devices for the treatment and diagnosis of abnormal heart rhythms.

30 Sep 2009

SNM calls on Congress to support the CARE Bill

SNM is calling on Congress to support the Consistency, Accuracy, Responsibility and Excellence in Medical Imaging and Radiation Therapy Act (CARE bill), which would ensure that states set minimum education and credentialing standards for nuclear medicine technologists. The bill (H.R. 3652) was introduced Sept. 28 in the U.S. House of Representatives by Rep. John Barrow (D-Ga.).

30 Sep 2009

Medgenics announces unaudited half-yearly results for the six months ended 30 June 2009

Medgenics (AIM:MEDG) (AIM:MEDU) is pleased to announce its unaudited half-yearly results for the six months ended 30 June 2009.

30 Sep 2009

Tβ4 therapy in EAE mice improves neurological functional recovery

REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that researchers at the Henry Ford Health System in Detroit, Michigan, demonstrated for the first time that Tβ4 treatment of EAE (experimental autoimmune encephalomyelitis – an animal model for multiple sclerosis) significantly improves neurological functional recovery.

30 Sep 2009

Sanofi-aventis announces study results comparing efficacy of Lantus to detemir

Sanofi-aventis announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine (rDNA) injection) compared to twice-daily insulin detemir. The study was presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.

30 Sep 2009

New anticoagulant therapy has fewer side-effects than warfarin

In an article reviewed by F1000 Medicine Faculty Members Robert Ruff, Brian Olshansky and Luis Ruilope, the blood-thinner dabigatran is shown to protect against stroke, blood clotting and major bleeding as effectively as warfarin, but with fewer side effects.

30 Sep 2009

Burzynski Research Institute and BBSF sign Research Agreement

The Burzynski Research Institute, Inc. (BRI) today announced that it has signed a Research Agreement with the UAB Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility (BBSF) that will provide biostatistical and data management support for BRI’s ongoing Phase II and Phase III protocol studies of Antineoplaston (ANP) treatment for gliomas.

30 Sep 2009

Université Laval unveils Treatment Compliance Chair to improve population health

The Faculty of Pharmacy at Université Laval sees the creation of the Treatment Compliance Chair as a means to help improve population health and well-being. Medication is a part of everyday life for many Quebecers.

30 Sep 2009

AFRESA Inhalation Powder and AFRESA Inhaler NDA under FDA review

AFRESA® (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin able to more closely replicate normal glucose suppression than currently available insulins, according to data presented at the 45th Annual Meeting of the European Association for the Study of Diabetes.

30 Sep 2009

ABL partners with Evivar Medical to develop and commercialize clinical management tools

Advanced Biological Laboratories S.A (ABL) and Evivar Medical Pty Ltd (Evivar) today announced the completion of agreements to cross-licence their respective intellectual property portfolios, and to form strategic alliances based on the use of their proprietary disease management platforms in HIV and Hepatitis B.

30 Sep 2009

Is using health resources less expensively "rationing?"

Critics of the Democrats' health care overhaul effort see veiled "rationing" schemes behind plans to curb misused and overused tests, treatments and drugs that drive up medical costs without helping patients, The Washington Post reports.

30 Sep 2009

Response Genetics launches new genetic diagnostic test for gastric cancer

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today the availability of its ResponseDX: Gastric™ genetic test panel, a proprietary PCR-based diagnostic test. By analyzing the expression of genes that correlate with response to commonly used chemotherapy agents, physicians can better tailor treatment for their patients with gastric cancer and gastroesophageal (GE) junction cancer.

29 Sep 2009

San Francisco Medical Center acquires a BSD-500 Hyperthermia System

BSD Medical Corporation announced today that the University of California, San Francisco Medical Center (UCSF) has acquired a BSD-500 Hyperthermia System (BSD-500). UCSF is a world leader in hyperthermia and has the largest and most versatile hyperthermia program on the West Coast, and its world-renowned Radiation Oncology team has added the capabilities of the BSD-500 to its growing hyperthermia cancer treatment program.

29 Sep 2009

90-day supply program to improve overall healthcare

Walgreens (NYSE:WAG) today launched a broad initiative for 90-day prescriptions that promotes delivery of maintenance and chronic care medication through its national network of more than 7,000 community pharmacies and employer worksite centers.

29 Sep 2009

Therapy News and Research

EMD Serono submits NDA for Cladribine Tablets in the U.S.

National Institutes of Health awards $16.8 million grant to Hutchinson Center/UW group

MacuSight's clinical development update on its proprietary ocular sirolimus product

Amicus Therapeutics to initiate Phase 1 study of AT2220

Lumenis to discuss different treatment options for laryngeal cancer at 2009 AAO-HNS

Æterna Zentaris announces results of its cetrorelix pamoate clinical development program TQT trial

St. Jude Medical launches new cardiac rhythm management devices

SNM calls on Congress to support the CARE Bill

Medgenics announces unaudited half-yearly results for the six months ended 30 June 2009

Tβ4 therapy in EAE mice improves neurological functional recovery

Sanofi-aventis announces study results comparing efficacy of Lantus to detemir

New anticoagulant therapy has fewer side-effects than warfarin

Burzynski Research Institute and BBSF sign Research Agreement

Université Laval unveils Treatment Compliance Chair to improve population health

AFRESA Inhalation Powder and AFRESA Inhaler NDA under FDA review

ABL partners with Evivar Medical to develop and commercialize clinical management tools

Is using health resources less expensively "rationing?"

Response Genetics launches new genetic diagnostic test for gastric cancer

San Francisco Medical Center acquires a BSD-500 Hyperthermia System

90-day supply program to improve overall healthcare

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News